Improving phase 2/3 trials with an enhanced 2-in-1 adaptive design
Open Access
- 15 July 2025
- journal article
- Published by Elsevier in Contemporary Clinical Trials Communications
- Vol. 47, 101524
Abstract
No abstract availableKeywords
Funding Information
- Sanofi US
This publication has 10 references indexed in Scilit:
- Flexible seamless 2-in-1 design with sample size adaptationJournal of Biopharmaceutical Statistics, 2024
- Application of Group Sequential Methods to the 2-in-1 Design and Its Extensions for Interim MonitoringStatistics in Biopharmaceutical Research, 2023
- An adaptive seamless Phase 2-3 design with multiple endpointsStatistical Methods in Medical Research, 2021
- The extension of 2-in-1 adaptive phase 2/3 designs and its application in oncology clinical trialsContemporary Clinical Trials, 2020
- Extensions of the 2-in-1 adaptive designContemporary Clinical Trials, 2020
- Adaptive expansion of biomarker populations in phase 3 clinical trialsContemporary Clinical Trials, 2018
- A 2-in-1 adaptive phase 2/3 design for expedited oncology drug developmentContemporary Clinical Trials, 2018
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- The One-Sided Barrier Problem for Gaussian NoiseBell System Technical Journal, 1962